NexGel (NXGL)
Nasdaq Market Closed
NexGel, Inc. is a healthcare materials and consumer products company focused on hydrogels: water-rich polymer gels that can be engineered for direct contact with skin and tissue. Its core capability is the production of high-water-content, electron beam cross-linked aqueous polymer hydrogels. This manufacturing approach allows the company to create sterile, flexible, and absorbent gel materials used in applications such as wound care, diagnostic electrodes, transdermal delivery systems, and cosmetic treatments.
The company serves both business-to-business customers and consumer markets. For medical and healthcare clients, NexGel develops and manufactures customized gel components that may be incorporated into wound dressings, pads, electrodes, or other products where moisture management, cushioning, cooling, or skin compatibility are important. Its hydrogel technology can be adapted through variations in formulation, coating, mixing, and cross-linking processes, giving customers a way to tailor gels for specific performance requirements.
NexGel also markets consumer-facing products built around its gel expertise, including items positioned for skin care, beauty, pain relief, and over-the-counter wound care. This combination of contract manufacturing and branded products distinguishes the company from firms that operate only as materials suppliers.
As a listed micro-cap healthcare and materials stock, NexGel’s investment profile is tied to its ability to commercialize specialized gel products, win manufacturing relationships, expand retail or direct-to-consumer distribution, and scale production efficiently. The company operates in niche markets where product quality, regulatory awareness, and manufacturing consistency are central to customer adoption.
Last updated
- Market Cap
- 5.39M
- P/E
- —
- P/FCF
- —
- P/S
- 0.48
- Enterprise Value
- 7.95M
- Sector
- Health Care
- Industry
- Surgical and Medical Instruments and Apparatus
- Address
- 2150 CABOT BLVD WEST,, LANGHORNE, PA, 19047
NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET
NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx
NEXGEL to Report First Quarter 2025 Financial Results on May 13th
NEXGEL Announces $2,000,000 Registered Direct Offering
NEXGEL Appoints Kip Crecca to its Scientific Advisory Board
NEXGEL projects increased revenue in upcoming quarters - Investing.com
NEXGEL and STADA Partner to Launch Leading European DAO Enzyme Supplement, Histasolv, in North America
NEXGEL Acquires International Beauty Brand, Silly George
NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year
NEXGEL to Present at the iAccess Alpha Best Ideas Spring Virtual Conference on March 12th
NEXGEL Subsidiary, CG Converting and Packaging, Begins 12,000 Square Foot Expansion of Texas Facility to Support the Expected Growth in Product Demand in 2024
NEXGEL to Participate in the LD Micro Main Event XVI on October 3rd
NEXGEL to Report Second Quarter 2023 Financial Results on August 14th
NEXGEL Partners with Enigma Health to Distribute its Leading Products in Retail Stores throughout North America
NEXGEL to Report First Quarter 2023 Financial Results on May 15th
NEXGEL Reports Fourth Quarter and Full Year 2022 Financial Results
NEXGEL to Report Fourth Quarter and Full Year 2022 Financial Results on March 27th
NEXGEL Acquires 50% Interest in Newly Formed Joint Venture with C.G. Laboratories for Converting and Packaging Business
NEXGEL Launches Turfguard to Treat Painful Turf Burns and Protect Sports-Related Wounds
NEXGEL Reports Third Quarter 2022 Financial Results
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 5.39M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 7.95M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 1.35
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 0.48
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -2.56
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 0.71
- EPS
- -0.35
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -1.49M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -80.5%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -27.72%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.69
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 1.12
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 0.44
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.06
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 156.03K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 0.59
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 2.65M | 2.8M | 2.93M | 2.88M | 2.81M |
| Gross profit | 1.06M | 819K | 1.24M | 1.26M | 1.19M |
| Operating income | -958K | -1.21M | -725K | -636K | -777K |
| EBITDA | -859K | -1.1M | -612K | -537K | -663K |
| Net income | -927K | -970K | -653K | -665K | -712K |
| Basic EPS | -0.11 | -0.12 | -0.08 | -0.09 | -0.09 |
| Diluted EPS | -0.11 | -0.12 | -0.08 | -0.09 | -0.09 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 11.6M | 10.46M | 11.62M | 9.71M | 10.44M |
| Total liabilities | 7.12M | 5.57M | 6.04M | 4.66M | 4.87M |
| Total equity | 4.48M | 4.89M | 5.58M | 5.06M | 5.57M |
| Cash & equivalents | 208K | 317K | 938K | 725K | 1.19M |
| Current assets | 3.72M | 3.6M | 4.68M | 4.16M | 4.74M |
| Current liabilities | 3.31M | 2.96M | 3.31M | 2.4M | 2.52M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -504K | 281K | -785K | -407K | -400K |
| Investing cash flow | -9K | -40K | -8K | -20K | — |
| Financing cash flow | 1.58M | -1.04M | 1.93M | -40K | -215K |
| Change in cash | 1.06M | -800K | 1.13M | -467K | -615K |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | PRE 14A — NEXGEL, INC. | View Filing | |
| edgar index | 4 — NEXGEL, INC. | View Filing | |
| form 4 | Form 4 — Levy Adam R. | View Filing | |
| form 4 | Form 4 — Levy Adam R. | View Filing | |
| edgar index | 144 — NEXGEL, INC. | View Filing | |
| form 4 | Form 4 — Levy Adam R. | View Filing | |
| edgar index | 3 — NEXGEL, INC. | View Filing | |
| edgar index | 3 — NEXGEL, INC. | View Filing | |
| edgar index | 4 — NEXGEL, INC. | View Filing | |
| edgar index | 4 — NEXGEL, INC. | View Filing | |
| edgar index | 4 — NEXGEL, INC. | View Filing | |
| form 3 | Form 3 — Kieser Brian Joseph | View Filing | |
| form 3 | Form 3 — Kieser Brian Joseph | View Filing | |
| edgar index | 8-K — NEXGEL, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 10-Q — NEXGEL, INC. | View Filing | |
| form 4 | Form 4 — Levy Adam R. | View Filing | |
| form 4 | Form 4 — Levy Adam R. | View Filing | |
| form 4 | Form 4 — Henry Scott Robert | View Filing | |
| form 4 | Form 4 — Henry Scott Robert | View Filing | |
| edgar index | 8-K — NEXGEL, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Kieser Brian Joseph | View Filing | |
| form 4 | Form 4 — Kieser Brian Joseph | View Filing | |
| edgar index | 3 — NEXGEL, INC. | View Filing | |
| form 3 | Form 3 — Blackman Ian Howard | View Filing | |
| form 3 | Form 3 — Blackman Ian Howard | View Filing | |
| form 3 | Form 3 — Blackman Ian Howard | View Filing | |
| edgar index | SCHEDULE 13G/A — NEXGEL, INC. | View Filing | |
| edgar index | 8-K — NEXGEL, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — NEXGEL, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G — NEXGEL, INC. | View Filing | |
| edgar index | 8-K — NEXGEL, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — NEXGEL, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 424B5 — NEXGEL, INC. | View Filing | |
| edgar index | 8-K — NEXGEL, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — NEXGEL, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — NEXGEL, INC. | View Filing | |
| form 4 | Form 4 — Levy Adam R. | View Filing | |
| edgar index | 144 — NEXGEL, INC. | View Filing | |
| form 4 | Form 4 — Levy Adam R. | View Filing | |
| edgar index | 8-K — NEXGEL, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — NEXGEL, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 10-Q — NEXGEL, INC. | View Filing | |
| edgar index | 8-K — NEXGEL, INC. | View Filing | |
| edgar index | 4 — NEXGEL, INC. | View Filing | |
| form 4 | Form 4 — Levy Adam R. | View Filing | |
| edgar index | DEF 14A — NEXGEL, INC. | View Filing | |
| edgar index | PRE 14A — NEXGEL, INC. | View Filing | |
| edgar index | 4 — NEXGEL, INC. | View Filing | |
| edgar index | 4 — NEXGEL, INC. | View Filing | |
| form 4 | Form 4 — Levy Adam R. | View Filing | |
| form 4 | Form 4 — Henry Scott Robert | View Filing | |
| edgar index | 144 — NEXGEL, INC. | View Filing | |
| form 4 | Form 4 — Levy Adam R. | View Filing | |
| form 4 | Form 4 — Henry Scott Robert | View Filing | |
| edgar index | 4 — NEXGEL, INC. | View Filing | |
| edgar index | 144 — NEXGEL, INC. | View Filing | |
| form 4 | Form 4 — Henry Scott Robert | View Filing | |
| edgar index | 4 — NEXGEL, INC. | View Filing | |
| edgar index | 144 — NEXGEL, INC. | View Filing | |
| form 4 | Form 4 — Levy Adam R. | View Filing | |
| edgar index | 8-K — NEXGEL, INC. | View Filing | |
| edgar index | 10-Q — NEXGEL, INC. | View Filing | |
| edgar index | 8-K — NEXGEL, INC. | View Filing | |
| edgar index | 3 — NEXGEL, INC. | View Filing | |
| form 3 | Form 3 — Ciardiello Steven | View Filing |